A new HER2-targeted regimen may push survival closer to two years for some patients with gastroesophageal cancer, according ...

Kyle Donahue, who was given months to live after receiving a diagnosis of glioblastoma in 2021, enrolled in a clinical trial ...

The American Cancer Society’s 2026 Cancer Statistics report shows the five-year survival rate for all cancers has reached a ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

Compartmentalizing fear and embracing teachings from Ben Sira and Buddhist philosophy aid in managing anxiety about the ...

Nutritional support enhances treatment continuity in malnourished patients with advanced gastric cancer and independently ...

Dr. Benjamin Jon Golas of Hackensack Meridian Health discussed the main strategies for treating pancreas cancer, focusing on ...

Kyle Donahue, who enrolled in a clinical trial at Brigham and Women's Hospital, is now a five-year survivor of brain cancer.

Dr. Benjamin Jon Golas explains that surgery, chemotherapy and radiation form the foundation of curative-intent treatment for patients with pancreas cancer.

The trial used CAN-3110, an engineered herpes virus, to target and kill glioblastoma tumor cells. CURE sat down with Dr. E.

Reolysin and Tecentriq combination therapy achieved a 29% objective response rate in third-line metastatic squamous cell anal ...

Improving equitable access to genomics-based clinical trials remains a critical priority in cancer care, according to Dr.